Bhagirathbhai R Dholaria
Overview
Explore the profile of Bhagirathbhai R Dholaria including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
343
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Costa L, Medvedova E, Dhakal B, Dholaria B, Godby K, Bal S, et al.
Blood Cancer J
. 2025 Feb;
15(1):13.
PMID: 39910064
No abstract available.
2.
Kongtim P, Vittayawacharin P, Zou J, Srour S, Shaffer B, Shapiro R, et al.
Transplant Cell Ther
. 2024 Sep;
30(12):1139-1154.
PMID: 39260570
Donor-specific anti-HLA antibodies (DSA) are an important cause of engraftment failure and may negatively impact survival outcomes of patients receiving allogeneic hematopoietic stem cell transplantation (HSCT) using an HLA-mismatched allograft....
3.
Callander N, Silbermann R, Kaufman J, Godby K, Laubach J, Schmidt T, et al.
Blood Cancer J
. 2024 Apr;
14(1):69.
PMID: 38649340
In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/dexamethasone (D-RVd) improved outcomes for transplant-eligible NDMM. Here, we present...
4.
Fraebel J, Park S, Shah R, Prieto-Granada C, Mason E, Sengsayadeth S, et al.
Bone Marrow Transplant
. 2024 Mar;
59(6):900-903.
PMID: 38467749
No abstract available.
5.
Iqbal M, Jagadeesh D, Chavez J, Khurana A, Rosenthal A, Craver E, et al.
Bone Marrow Transplant
. 2023 Nov;
59(2):211-216.
PMID: 37973893
Outcomes are poor for patients with relapsed and/or refractory (R/R) large B-cell lymphoma (LBCL) post chimeric antigen receptor T-cell (CAR-T) therapy. Two CD19-directed therapies, tafasitamab- cxix plus lenalidomide (tafa-len) and...
6.
Costa L, Chhabra S, Medvedova E, Dholaria B, Schmidt T, Godby K, et al.
Lancet Haematol
. 2023 Sep;
10(11):e890-e901.
PMID: 37776872
Background: For patients with newly diagnosed multiple myeloma, reaching minimal residual disease (MRD) negativity after treatment is associated with improved outcomes; however, the use of MRD to modulate therapy remains...
7.
Gorsline C, Staub M, Nelson G, Nesbitt W, Dholaria B, Satyanarayana G
Antimicrob Steward Healthc Epidemiol
. 2022 Sep;
1(1):e22.
PMID: 36168451
In a survey of adult hospital providers regarding antibiotic use in the treatment of febrile neutropenia, clinical fellows, and pharmacists showed higher comfort levels with early antimicrobial de-escalation compared to...
8.
Riedell P, Hwang W, Nastoupil L, Pennisi M, McGuirk J, Maziarz R, et al.
Transplant Cell Ther
. 2022 Jul;
28(10):669-676.
PMID: 35850429
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-directed chimeric antigen receptor (CAR) T cell therapies approved for the treatment of relapsed/refractory aggressive B cell lymphomas. We present a multicenter retrospective...
9.
Bhaskar S, Dholaria B, Sengsayadeth S, Savani B, Oluwole O
EJHaem
. 2022 Jul;
3(Suppl 1):39-45.
PMID: 35844303
Chimeric antigen receptor (CAR) T-cell therapy has been approved for use in several relapsed/refractory hematologic malignancies and has significantly improved outcomes for these diseases. A number of different CAR T...
10.
Sengsayadeth S, Dholaria B, Savani B, Oluwole O
EJHaem
. 2022 Jul;
3(Suppl 1):3-5.
PMID: 35844302
No abstract available.